O’Grady T, Wang X, Honer Zu Bentrup K, Baddoo M, Concha M et al (2016) Global tran-
script structure resolution of high gene density genomes through multi-platform data integra-
tion. Nucleic Acids Res 44:e145
Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D et al (2012) The viral and cellular
microRNA targetome in lymphoblastoid cell lines. PLoS Pathog 8:e1002484
Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J et al (2016) Epstein-Barr viral
miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing.
J Exp Med 213:2065–2080
Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D et al (2016) Epstein-Barr virus microR-
NAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci U S A
113:E6467–e6475
Ersing I, Nobre L, Wang LW, Soday L, Ma Y et al (2017) A temporal proteomic map of
Epstein-Barr virus lytic replication in B cells. Cell Rep 19:1479–1493
Etoh T, Baba H, Taketomi A, Nakashima H, Kohnoe S et al (1998) Sequential methothrextate
and 5-fruororacil therapy for diffuse bone metastasis from gastric cancer. Anticancer Res
18:2085–2088
Gray NA, Kapojos JJ, Burke MT, Sammartino C, Clark CJ (2016) Patient kidney disease
knowledge remains inadequate with standard nephrology outpatient care. Clin Kidney
J 9:113–118
Meissner MH (2010) Conventional anticoagulant therapy remains the current standard of
care for the treatment of iliofemoral deep venous thrombosis. Dis Mon 56:642–652
Knight JS, Sharma N, Kalman DE, Robertson ES (2004) A cyclin-binding motif within
the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin
A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol 78:12857–12867
Choudhuri T, Verma SC, Lan K, Murakami M, Robertson ES (2007) The ATM/ATR signal-
ing effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M
cell cycle block. J Virol 81:6718–6730
Saha A, Halder S, Upadhyay SK, Lu J, Kumar P et al (2011) Epstein-Barr virus nuclear
antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1.
PLoS Pathog 7:e1001275
Yi F, Saha A, Murakami M, Kumar P, Knight JS et al (2009) Epstein-Barr virus nuclear
antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology
388:236–247
Saha A, Bamidele A, Murakami M, Robertson ES (2011) EBNA3C attenuates the func-
tion of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol
85:2079–2088
Pei Y, Banerjee S, Sun Z, Jha HC, Saha A et al (2016) EBV nuclear antigen 3C mediates
regulation of E2F6 to inhibit E2F1 transcription and promote cell proliferation. PLoS Pathog
12:e1005844
DeLong WB, Polissar NL, Neradilek MB, Laam LA (2015) To the Editor: Re: Controversy:
acute cauda equina syndrome caused by a disk lesion: is emergent surgery the correct option?
In: Mahadevappa et al. (ed) Surgical decompression remains the standard of care, by McLain
et al. Spine (Phila Pa 1976) 40: E1120
Shumilov A, Tsai MH, Schlosser YT, Kratz AS, Bernhardt K et al (2017) Epstein-Barr
virus particles induce centrosome amplification and chromosomal instability. Nat Commun
8:14257
Crowther M, Donadini MP (2010) Hematology/oncology clinics of North America.
Hypercoagulable states and new anticoagulants. Preface. Hematol Oncol Clin North Am
24:xiii–xxiv
Brown JR (2013) Hematology/oncology clinics of North America. Chronic lymphocytic leu-
kemia. Preface. Hematol Oncol Clin North Am 27:xiii–xxiv
Jox A, Rohen C, Belge G, Bartnitzke S, Pawlita M et al (1997) Integration of Epstein-Barr
virus in Burkitt’s lymphoma cells leads to a region of enhanced chromosome instability. Ann
Oncol 8(Suppl 2):131–135
